GlassScriptPhysician profile
John R Greene
NPI 1558327031
$1,522.39
in general payments reported to CMS, 2019-2025
17 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.13 · 2021: $129 · 2022: $135 · 2023: $100 · 2024: $487 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $471.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $220.57 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.15 | 2020-2025 | Jardiance |
| Abbvie INC. | $153.70 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $110.49 | 2022-2024 | |
| Lilly USA, LLC | $100.54 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Ardelyx, INC. | $83.53 | 2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.34 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $32.12 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $17.37 | 2025 | Capvaxive |
| Viatris Specialty LLC | $17.00 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $15.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.93 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $14.61 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.72 | 2025 | Opsumit, Uptravi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.